Clasificación en acciones
#28270
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to... Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Precio por acción
$0.0183374
Última sincronización: 2026-08-19
Capitalización bursátil
$27.51M
Comercio Syntara Limited (SNT)
Precio SNT con Capital del mercado a B
Capitalización de mercado de Syntara Limited(SNT)
Capitalización bursátil: $27.51M
A fecha de August 2026, Syntara Limited tiene una capitalización de mercado de $27.51M. Esto convierte a Syntara Limited en la 28270th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Syntara Limited desde 2003 hasta 2026
SNT en comparación con los más populares 5 títulos stocks
| Precio por SNT |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.301T
|
+19,267,682.92%
|
|
|
|
|
$4.634T
|
+16,843,248.04%
|
|
|
|
|
$4.143T
|
+15,058,953.48%
|
|
|
|
|
$3.589T
|
+13,046,679.38%
|
|
|
|
|
$2.857T
|
+10,384,438.20%
|
